Advertisement

Advertisement

prostate cancer

SNMMI 2017: PET/CT, Clinical Management, and Disease Detection in Prostate Cancer

An estimated one in seven American men will be affected by prostate cancer in their lifetime. Prostate-specific molecular imaging can help to clinically manage the disease much more efficiently, especially if the cancer returns, according to research revealed at the 2017 Annual Meeting of the...

Prostate Cancer

Ipilimumab vs Placebo in Metastatic Chemotherapy-Naive, Castration-Resistant Prostate Cancer Without Visceral Metastases

In the phase III CA184-095trial reported in the Journal of Clinical Oncology, Tomasz M. Beer, MD, FACP, of the Knight Cancer Institute, Oregon Health and Science University, and colleagues found that ipilimumab (Yervoy) did not increase overall survival vs placebo in men with asymptomatic or...

Prostate Cancer

Androgen Blockade and Salvage ­Radiation Therapy in Prostate Cancer: Cautious Optimism Amid Unanswered Questions

The recent report of results of RTOG 9601 by Shipley et al in The New England Journal of Medicine1—reviewed in this issue of The ASCO Post—strongly supports the variably used practice of adding “androgen blockade” to salvage radiation therapy in men with a rising prostate-specific antigen (PSA)...

Prostate Cancer

Survival Benefit of Adding Antiandrogen Therapy to Radiation in Recurrent Prostate Cancer: Final Results of RTOG 9601

As reported in The New England Journal of Medicine by W.U. Shipley, MD, of Massachusetts General Hospital and Harvard Medical School, and colleagues in the NRG Oncology Radiation Therapy Oncology Group (RTOG), the final analysis of the phase III RTOG 9601 trial shows that the addition of...

prostate cancer

T2:ERG and PCA3 RNA Urinary Testing for Detecting Aggressive Prostate Cancer

Combined testing for urinary PCA3 and TMPRSS2:ERG (T2:ERG) RNA may increase accuracy in identifying the risk for aggressive early prostate cancer, according to a study reported in JAMA Oncology by Sanda et al in the EDRN-PCA3 Study Group. Study Details The study involved 516 development cohort...

prostate cancer

Tanya B. Dorff, MD, and Sumanta K. Pal, MD, on Prostate Cancer: Expert Perspectives on STAMPEDE and a Phase IV Trial

Tanya B. Dorff, MD, of the USC Norris Comprehensive Cancer Center, and Sumanta K. Pal, MD, of the City of Hope, discuss two key presentations on prostate cancer: findings on adding abiraterone for men with high-risk prostate cancer starting long-term androgen-deprivation therapy, and an after-market study on continuing enzalutamide post PSA progression in men with chemotherapy-naive metastatic castration-resistant prostate cancer. (Abstracts LBA5003, 5004)

prostate cancer

Neeraj Agarwal, MD, and Sumanta K. Pal, MD, on Prostate Cancer: Expert Perspectives on the LATITUDE Trial

Neeraj Agarwal, MD, of Huntsman Cancer Institute, and Sumanta K. Pal, MD, of the City of Hope, examine the study findings on androgen-deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. (Abstract LBA3)

prostate cancer

LATITUDE Trial: Adding Abiraterone and Prednisone to Androgen-Deprivation Therapy in Metastatic Castration-Sensitive Prostate Cancer

As reported in the Plenary Session at the 2017 ASCO Annual Meeting and in The New England Journal of Medicine by Fizazi et al, the phase III LATITUDE trial has shown that the addition of abiraterone acetate (Zytiga) and prednisone to androgen-deprivation therapy resulted in marked improvements in...

prostate cancer

Gerhardt Attard, MD, PhD, on Prostate Cancer: Results From an After-Market Study on Enzalutamide

Gerhardt Attard, MD, PhD, of The Royal Marsden Hospital and The Institute of Cancer Research, discusses trial results on continued enzalutamide post prostate-specific antigen progression in men with chemotherapy-naive metastatic castration-resistant prostate cancer. (Abstract 5004)

prostate cancer

Nicholas D. James, MBBS, PhD, on Prostate Cancer: Results From the STAMPEDE Trial

Nicholas D. James, MBBS, PhD, of Queen Elizabeth Hospital, discusses study findings on adding abiraterone for men with high-risk prostate cancer starting long-term androgen-deprivation therapy (Abstract LBA5003).

prostate cancer

Karim Fizazi, MD, PhD, on Prostate Cancer: Results From the LATITUDE Trial

Karim Fizazi, MD, PhD, of the University Paris-Sud, discusses study findings on androgen-deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. (Abstract LBA3)

prostate cancer

ASCO 2017: LATITUDE Trial: Addition of Abiraterone to Standard Hormonal Therapy Improves Outcomes in Newly Diagnosed Metastatic Prostate Cancer

Adding abiraterone acetate (Zytiga) plus prednisone to standard hormonal therapy for men newly diagnosed with high-risk, metastatic prostate cancer lowers the chance of death by 38%. In a phase III clinical trial of 1,200 men, abiraterone also more than doubled the median time until the cancer...

prostate cancer

ASCO 2017: STAMPEDE Trial: Adding Abiraterone to Standard Treatment Improves Survival in Advanced Prostate Cancer

The STAMPEDE clinical trial of nearly 2,000 men shows that adding abiraterone acetate (Zytiga) to a standard initial treatment regimen for high-risk, advanced prostate cancer lowers the relative risk of death by 37%. The 3-year survival rate was 76% with standard therapy alone vs 83% with standard...

prostate cancer

Clinical Implications of Luminal and Basal Subtyping of Prostate Cancer

As reported by Zhao et al in JAMA Oncology, luminal B prostate cancers carry a worse overall prognosis than luminal A and basal-like cancers, but luminal B tumors respond better to postoperative androgen-deprivation therapy. Study Details In the study, the PAM50 classifier was used to subtype...

Prostate Cancer

What Is Appropriate Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer?

As the subtleties of metastatic prostate cancer become increasingly recognized, treatment should evolve accordingly, said Jessica M. Clement, MD, Assistant Professor of Medicine at the University of Connecticut Health System and Neag Cancer Center, Farmington. Of particular interest to Dr. Clement ...

Prostate Cancer

ASCO Provisional Clinical Opinion on Hormonal Therapy for Castration-Resistant Prostate Cancer

On April 25, ASCO issued a provisional clinical opinion on the use of second-line hormonal therapy for men with castration-resistant prostate cancer who have not yet received chemotherapy. The recommendations of this provisional clinical opinion were informed by evidence from a systematic review of ...

prostate cancer

AUA 2017: Studies Highlight Shifts in Prostate Cancer Screening and Management

Active surveillance in men under 60, use of telemedicine in the management of prostate cancer, and physicians' personal prostate cancer screening preferences were all highlighted at the 2017 Annual Scientific Meeting of the American Urological Association (AUA). Active Surveillance for Low-Risk...

prostate cancer

AUA 2017: Association of Oncotype DX Genomic Prostate Score Test With Prostate Cancer–Specific Death and Metastases in Early-Stage Disease

New results presented at the 2017 American Urological Association (AUA) Annual Meeting from a large, community-based, multicenter clinical validation study conducted at Kaiser Permanente confirmed that the Oncotype DX Genomic Prostate Score (GPS) test is a strong independent predictor of prostate...

prostate cancer

AUA 2017: New Studies Demonstrate Impact of BRCA, DNA Repair Gene Mutations in Prostate Cancer

Data presented at the 2017 Annual Scientific Meeting of the American Urological Association (AUA) showed new findings related to the impact of certain genetic mutations on the risk and development of prostate cancer, in particular metastatic disease. Male BRCA Mutations An analysis by Mano et al...

prostate cancer

ESTRO 2017: HDR Brachytherapy in Prostate Cancer Does Not Cause Higher Toxicity, Results in High Patient Satisfaction

Treating prostate cancer with a single, high dose of radiation delivered precisely to the site of the tumor results in good quality of life and fewer trips to the hospital, with adverse side effects that are no worse than if the radiation treatment had been given in several lower doses. These...

prostate cancer

ASCO Provisional Clinical Opinion: Second-Line Hormonal Therapy for Chemotherapy-Naive Castration-Resistant Prostate Cancer

As reported by Katherine S. Virgo, PhD, MBA, of Emory University, and colleagues in the Journal of Clinical Oncology, ASCO has issued a provisional clinical opinion on second-line hormonal therapy for chemotherapy-naive castration-resistant prostate cancer. The provisional clinical opinion applies...

prostate cancer

Prostate-Specific Antigen Testing Rates Appear to Level Off After Recent Drop

Declines in prostate-specific antigen (PSA) testing that came after changes in government screening guidelines have abated in recent years, according to a new study. In JAMA Internal Medicine, American Cancer Society (ACS) investigators led by Stacy A. Fedewa, PhD, wrote that about 1 in 3 men aged...

Prostate Cancer

Progress in Defining Molecular Signature for Aggressive Androgen-Indifferent Prostate Cancer

Prostate cancer has lagged behind breast cancer in the identification of predictive and prognostic biomarkers, but the field is catching up. Researchers have identified a molecular signature that can distinguish aggressive prostate cancer that is androgen-indifferent and will have a better response ...

Kidney Cancer
Prostate Cancer
Cost of Care

Next-Generation Genitourinary Oncology: Keeping One’s Powder Dry

There is a new yin-yang of management in genitourinary oncology, with the balance of opposing power focused among cancer cells, kinase inhibition, and lymphocyte function, representing a shift in the fashions of treatment somewhat away from chemotherapy. This linear progress has been complicated...

prostate cancer

Possible Link Between Androgen-Deprivation Therapy and Dementia

A new analysis of patients who have undergone treatment for prostate cancer shows a connection between androgen-deprivation therapy and dementia, according to researchers from the Perelman School of Medicine at the University of Pennsylvania. Previous studies from Penn have shown men who undergo...

prostate cancer

Predicting Metastatic Disease After Radical Prostatectomy

An individual patient-level meta-analysis has shown that the Decipher® (GenomeDx) genomic classifier is capable of distinguishing risk groups for metastatic disease after radical prostatectomy for prostate cancer. The study was reported by Spratt and colleagues in the Journal of Clinical...

prostate cancer

U.S. Preventive Services Task Force Seeks Comments on Draft Recommendation Statement on Screening for Prostate Cancer

On April 11, the U.S. Preventive Services Task Force (USPSTF) posted for public comment a draft recommendation statement and three draft evidence reviews on screening for prostate cancer. Through this draft recommendation, the Task Force is providing clinicians and their patients with...

prostate cancer

ASCO and Cancer Care Ontario Update Guideline on Radiation Therapy for Prostate Cancer

The American Society of Clinical Oncology (ASCO) and Cancer Care Ontario today issued a joint clinical practice guideline update on brachytherapy for patients with prostate cancer. The update provides evidence-based recommendations for different patient risk groups and specifies the most effective...

prostate cancer

Hypofractionated vs Conventional Radiotherapy for Localized Prostate Cancer

Hypofractionated radiotherapy was noninferior to standard radiotherapy in biochemical-clinical failure disease-free survival in men with localized prostate cancer, according to a study reported by Catton et al in the Journal of Clinical Oncology. Study Details In the trial, 1,206 patients with...

prostate cancer

Celecoxib or Celecoxib/Zoledronic Acid in Men Initiating Hormone Therapy for Prostate Cancer

As reported by Mason et al in the Journal of Clinical Oncology, long-term survival results of the UK-based, multiarm, multistage platform–design STAMPEDE trial showed no survival benefit with the addition of celecoxib or celecoxib plus zoledronic acid in men initiating long-term hormone...

Prostate Cancer

Potential Surrogate for All-Cause Mortality Risk in Localized Prostate Cancer

In a study reported in JAMA Oncology, Trevor J. Royce, MD, of Harvard Radiation Oncology Program, Brigham and Women’s Hospital, and colleagues found that a prostate-specific antigen (PSA) nadir > 0.5 ng/mL may be a dominant risk factor for all-cause mortality after radiation therapy and...

Prostate Cancer

Expert Point of View: Joseph Greer, PhD

“These data are consistent with other studies we have conducted in advanced lung cancer, in which we similarly found that one-third of patients believed that their metastatic lung cancer was curable. These patients ostensibly already had conversations with their oncologists about their prognosis...

Prostate Cancer

Aligning Patient Expectations With Treatment Goals in the Metastatic Setting

More than one-third of men with incurable metastatic prostate cancer mistakenly believe that their cancer may be curable, according to a survey of patient expectations at an academic cancer center. “This study is part of a larger survey of treatment decision-making among men with metastatic...

prostate cancer

Testosterone Replacement Therapy and Risk of Prostate Cancer

In a Swedish study reported in the Journal of Clinical Oncology, Loeb et al found that use of testosterone replacement therapy was not associated with an increased risk of prostate cancer and was associated with a lower risk of aggressive cancer among men developing the disease. Study Details The ...

prostate cancer

Antisense Oligonucleotide Custirsen Combined With Docetaxel and Prednisone in Metastatic Prostate Cancer

In the phase III SYNERGY trial reported in The Lancet Oncology, Chi et al found that the addition of the second-generation antisense oligonucleotide custirsen to docetaxel and prednisone did not improve overall survival in patients with metastatic castration-resistant prostate cancer. Custirsen...

prostate cancer

European Cohort Study of Vasectomy and Prostate Cancer Risk

In a large European cohort study reported in the Journal of Clinical Oncology, Smith Byrne et al found that vasectomy was not associated with an increased overall risk of prostate cancer or death from prostate cancer but appeared to increase the risk of lower-grade disease. Other studies have...

prostate cancer

Preclinical Study Finds SPOP Mutation Drives Prostate Cancer Subtype

A genetically engineered mouse model developed by Blattner et al investigating the role of the gene Speckle Type BTB/POZ Protein, or SPOP, as a driver of prostate cancer has found that the mutation drives prostate neoplasia through coordinate deregulation of both P13K/mTOR and androgen receptor...

prostate cancer

Use of Evidence-Based Prostate Cancer Imaging in an Integrated Health-Care System

In a study reported in the Journal of Oncology Practice, Salloum et al found that use of nonindicated imaging for diagnostic staging of low-risk prostate cancer in a nonprofit integrated health-care system remained common but has decreased in frequency. As noted by the authors: “The overuse...

Prostate Cancer

Expert Point of View: Susan F. Slovin, MD, PhD

Formal discussant for the presentation of SWOG S9921 results, Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, New York, said there were some important points to understand about this “vintage” trial.  “The trial was designed 20 years ago, and the view is...

Prostate Cancer

No Benefit From Older Standard-of-Care Drug in Adjuvant Chemotherapy for High-Risk Prostate Cancer, but Newer Trials Feasible

An older trial designed to evaluate the benefits of adjuvant therapy following radical prostatectomy in patients with high-risk prostate cancer showed no difference in overall or disease-free survival between 2 years of androgen-deprivation therapy and 2 years of androgen-deprivation therapy plus...

breast cancer
prostate cancer
issues in oncology

Diana D. Jeffery, PhD, on Mental Health Comorbidities: Predictors of Cost and Utilization

Diana D. Jeffery, PhD, of the Defense Health Agency, discusses the need to screen for mental health comorbidities, including depression, anxiety, adjustment disorders, substance use disorders, and persistent mental illnesses, as shown in a study of breast and prostate cancer patients (Abstract 18).

prostate cancer

Single Dose of Brachytherapy May Be an Effective Treatment for Localized Prostate Cancer

Results from a new prospective clinical trial indicate that high–dose rate (HDR) brachytherapy administered in a single 19-Gy treatment may be a safe and effective alternative to longer courses of HDR treatment for men with localized prostate cancer. The study was reported by Krauss et al in...

breast cancer
prostate cancer
supportive care

ASCO Quality Care 2017: Mental Health Conditions Contribute to Care-Related Costs, Hospital Visits in Breast and Prostate Cancers

A new analysis of data from the U.S. Military Health System found that mood and adjustment disorders such as anxiety and depression were strong predictors of the annual number of outpatient visits, hospital admissions, and number of days in the hospital for patients with breast and prostate...

prostate cancer

Development of a Voided Urine Assay for Detecting Prostate Cancer Noninvasively

Scientists at the Sidney Kimmel Cancer Center at Thomas Jefferson University have developed a noninvasive technique to detect the presence of prostate cancer cells in patients' urine. The pilot study, led by Mathew L. Thakur, PhD, Director, Laboratories of Radiopharmaceutical Research and Molecular ...

prostate cancer

Guru Sonpavde, MD, on Prostate Cancer: Targeting DNA Alterations

Guru Sonpavde, MD, of the UAB Comprehensive Cancer Center, discusses his study on circulating tumor DNA alterations in metastatic castration-resistant prostate cancer and the therapeutic direction the data suggest. (Abstract 149)

prostate cancer

Paul L. Nguyen, MD, on Prostate Cancer: Active Surveillance

Paul L. Nguyen, MD, of the Dana-Farber Cancer Institute, summarizes a session he co-chaired, which included discussion of Canadian vs U.S. guidelines; ProtecT; genomic and hereditary tests; and imaging to guide active surveillance. (General Session 1)

prostate cancer

Paul L. Nguyen, MD, on Predicting Metastasis and Mortality

Paul L. Nguyen, MD, of the Dana-Farber Cancer Institute, discuses an evaluation of the Decipher prostate cancer classifier to predict metastasis and disease-specific mortality from genomic analysis of diagnostic needle biopsy specimens. (Abstract 4)

prostate cancer

Joshua M. Lang, MD, on Prostate Cancer: Best of the Journals

Joshua M. Lang, MD, of the University of Wisconsin Carbone Cancer Center, discusses genomic alterations in DNA damage–repair pathways––more common in patients with prostate cancer than previously recognized–– and clinical trials with PARP inhibitors.

prostate cancer

L. Michael Glodé, MD, on Prostate Cancer: Results From SWOG S9921

L. Michael Glodé, MD, of the University of Colorado Cancer Center, discusses study findings on adjuvant androgen deprivation vs mitoxantrone plus prednisone plus ADT in high-risk prostate cancer patients following radical prostatectomy. (Abstract 2)

prostate cancer

Charles G. Drake, MD, PhD, on Prostate Cancer and Immunology: Expert Perspective

Charles G. Drake, MD, PhD, of Columbia University Medical Center, summarizes his keynote lecture on immunotherapy as a new frontier in prostate cancer and its synergistic use with traditional treatments.

Advertisement

Advertisement

Advertisement